Pentazocine

Pentazocine

File:Pentazocine formula.svg
Systematic (IUPAC) name
(2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-h​exahydro-2,6-methano-3-benzazocin-8-ol or 2-dimethy​lallyl-5,​9-dimethy​l-2'-hydr​oxybenzom​orphan
Clinical data
Pregnancy category	C/D (U.S.)
Routes of administration	Oral, Insufflation, IV, IM
Legal status
Legal status	Schedule IV (U.S.)
Pharmacokinetic data
Bioavailability	~20% orally
Metabolism	Hepatic
Biological half-life	2 to 3 hours
Excretion	Renal
Identifiers
CAS Number	359-83-1
ATC code	N02AD01 (WHO)
PubChem	CID 441278
IUPHAR/BPS	1606
DrugBank	APRD01173
ChemSpider	390041
Chemical data
Formula	C19H27NO
Molar mass	285.424 g/mol[[]]
(verify)

Pentazocine is a synthetically-prepared prototypical mixed agonist-antagonist narcotic (opioid analgesic) drug of the benzomorphan class of opioids used to treat moderate to moderately severe pain. Pentazocine is sold under several brand names, such as Fortral, Talwin NX (with the μ-antagonist naloxone, will cause withdrawal in opioid dependent persons), Talwin, Talwin PX (without naloxone), Fortwin (Lactate injectable form) and Talacen (with acetaminophen). This compound may exist as one of two enantiomers, named (+)-pentazocine and (-)-pentazocine. (-)-pentazocine is a κ opioid receptor agonist, while (+)-pentazocine is not, instead displaying a ten-fold greater affinity for the σ receptor. Talwin PX is the main pentazocine pharmaceutical in Canada, where laws and regulations prohibit the addition of naloxone to the formulation for non-therapeutic purposes. Related drugs include phenazocine, dezocine, cyclazocine, salvinorin A (distantly) and several chemicals used in research on the central nervous system.

Development and government approval

Pentazocine was developed by the Sterling Drug Company, Sterling-Winthrop Research Institute, of Rensselaer, New York. It was approved by the Food and Drug Administration in June 1967 after being favorably reviewed following testing on 12,000 patients in the United States. The analgesic compound was first made at Sterling in 1958. U.S. testing was conducted between 1961 - 1967. By mid 1967 Pentazocine was already being sold in Mexico, England, and Argentina, under different trade names.

Adverse effects

Side effects are similar to those of morphine, but pentazocine may be more likely to cause hallucinations and other psychotomimetic effects; cardiovascular effects make it unsuitable for use in myocardial infarction. Unlike morphine, its respiratory depressant action is subject to a "ceiling" effect. 38 milligrams of pentazocine has the same pain relieving capacity as 10 milligrams of morphine. It can be used as an analgesic for dental extractions except in patients dependent upon opioid agonists.

File:Pentazocine.jpg

Tissue damage at injection sites

Severe injection site necrosis and sepsis has occurred (sometime requiring amputation of limb) with multiple injection of pentazocine lactate (Sosegon, Fortwin). In addition, animal studies have demonstrated that Pentazocine is tolerated less well subcutaneously than intramuscularly.

Clinical use of Pentazocine

Pentazocine is used to treat moderate to severe pain

Recreational use

In the 1970s, recreational drug users discovered that combining pentazocine with tripelennamine (a first-generation ethylenediamine antihistamine most commonly dispensed under the brand names Pelamine and Pyribenzamine and used both clinically and on the street to potentiate opioids and mitigate some of the side effects like itching, especially of codeine and morphine) produced a euphoric sensation much like that brought on by heroin though subjectively different. Users who were already addicted to the latter often used this combination when heroin was unavailable. Since tripelennamine tablets are typically blue in color and brand-name Pentazocine is known as Talwin (hence "T's"), the pentazocine/tripelennamine combination acquired the slang name Ts and blues, a slang term analogous to the doors and fours of the same period - a combination of Tylenol #4 - Tylenol with 60mg of codeine - and Doriden, a trade name of glutethimide tablets, taken to achieve a similar effect.

Glutethimide is a CYP450-2D6 inducer that increases the degree of conversion of codeine to morphine (the active metabolite of codeine - a prodrug with no intrinsic activity), in vivo, by approximately a factor of three, increasing the average degree of codeine metabolized to morphine from 10% to 30% (thus increasing the activity of codeine by roughly 300%) - while synergistically adding to the depressant effects of the codeine.

After health-care professionals and drug-enforcement officials became aware of this scenario, the mu-opioid-antagonist naloxone was added to preparations containing pentazocine, and the reported incidence of its abuse has declined precipitously since. It is commonly asserted that the use of pentazocine with tripelennamine originated amongst dentists, doctors, and nurses in the Middle Western United States. A more recent recreational route is pentazocine combined with methylphenidate (Ritalin) via the oral route, insufflation or mixed intravenously.

Administration

Pentazocine is administered by subcutaneous (rarely), intramuscular, and intravenous injection as the lactate: The usual dose is the equivalent of pentazocine 30 to 60 mg every 3 to 4 hours; it should not be necessary to exceed 360 mg daily. It is also available in 25 mg pills.

In a study published in the March 24, 2003 issue of the Proceedings of the National Academy of Sciences, a team led by McGill University researcher Jeffrey Mogil found that women with red hair require less pentazocine for pain relief than do women with other hair colours or men of any hair colour.

Legal status

Pentazocine is still classified in Schedule IV under the Controlled Substances Act in the United States, even with the addition of Naloxone. Internationally, pentazocine is a Schedule III drug under the Convention on Psychotropic Substances.

External links

• Eurekalert report on PNAS article

de:Pentazocin